New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease

2022年09月06日 17:52:12 来自: (0)参与

InPedILD Phase III trial showed encouraging results for both primary endpoints. Full data were published in the European Respiratory Journal and presented at the European Respiratory Society International Congress in Barcelona, Spain
If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosing interstitial lung disease, addressing a high unmet need
Findings supplement the long-term and established clinical efficacy of nintedanib in adults, supporting Boehringer Ingelheim’s leadership in pulmonary fibrosis and determination to transform lives for generations

INGELHEIM, Germany & RIDGEFIELD, Conn.--(BUSINESS WIRE)--Today, Boehringer Ingelheim announced Phase III data from the InPedILD trial, which assessed the pharmacokinetics (dosing) and safety profile of nintedanib in children and adolescents between 6 and 17 years old with clinically significant fibrosing interstitial lung disease (ILD). The trial showed encouraging data for both primary endpoints and results were published in the European Respiratory Journal (ERJ) and presented at the European Respiratory Society International Congress (ERS) in Barcelona, Spain.1

“Based on the nintedanib mode of action, preclinical evidence and the clinical benefit in adults, there was a compelling rationale for examining its effect in children living with interstitial lung disease,” said the coordinating investigator, Prof. Robin Deterding, M.D., Director of the Breathing Institute, Children's Hospital Colorado. “This trial supports its potential use as a treatment with an acceptable safety profile for children and adolescents, for whom no approved evidence-based therapies exist.”

The InPedILD results showed that the weight-based dosing regimen of nintedanib in children and adolescents with fibrosing ILD resulted in comparable exposure to that observed in adult patients with fibrosing ILD. In addition, nintedanib had an acceptable safety and tolerability profile with no new safety signals observed when compared to adult patients with idiopathic pulmonary fibrosis (IPF), other progressive fibrosing interstitial lung disease (PF-ILD), and systemic sclerosis-associated interstitial lung disease (SSc-ILD).1 Based on these findings, regulatory applications will be submitted to the European Medicines Agency and U.S. Food and Drug Administration.

“While childhood interstitial lung diseases are very rare, their impact on children, teenagers and their loved ones can be devastating,” said Dr. Susanne Stowasser, Associate Head of Medicine Pulmonology at Boehringer Ingelheim. “The findings from InPedILD help meet the urgent need for well-characterized therapies for these children and adolescents living with ILD. These data further support Boehringer Ingelheim’s ongoing commitment to address unmet needs and advance research for people across all generations living with pulmonary fibrosis.”

Childhood interstitial lung disease (chILD) includes more than 200 rare disorders with debilitating symptoms that can include cough, difficulty breathing and rapid breathing.2,3 Its exact prevalence is unknown, but it can be considered very rare with a reported incidence ranging from 1.5 to 3.8 per million.2 Pulmonary fibrosis within chILD is even less frequent, with no known global prevalence estimates, and no international studies prior to InPedILD.2 chILD is associated with significant mortality and morbidity. When their condition deteriorates, many pediatric patients will need oxygen to go about their daily lives and require lung transplants.3,4 There are no established diagnostic criteria and few management guidelines.2,5,6 The current standard of care involves off-label use of treatments including steroids and steroid-sparing immunosuppressants, which have known adverse events and limited evidence for their use.2

Please click on the following link for ‘Notes to Editors’: https://www.boehringer-ingelheim.com/human-health/lung-diseases/pulmonary-fibrosis/new-data-nintedanib-children-fibrosing-ild

相关新闻
腾讯网友:夠鐘死心孒
评论:你都好意思骗我了,我哪好意思不信。

凤凰网友:腐朽Eros1on
评论:终于知道为什么吃奥利奥会先舔一下了,因为那样就没人会和你抢了。

淘宝网友:泡沫 forever/
评论:人生如同故事,重要的并不是有多长,而是在有多好。

本网网友:Sam| 绝情△
评论:天平的一端放上爱情,另一端就得放上生命

猫扑网友:记得牵绊的人
评论:在身材这个问题上,我是坚决不会承认自己是一个粗人的。

其它网友:昔年 °Cold
评论:我一直在希望的田野上奔跑,虽然也偶尔被失望绊倒。

百度网友:厮守°- Michae
评论:再多各自牛逼的时光,也比不上一起傻逼的岁月!

网易网友:昔年°  /21c
评论:人生就像愤怒的小鸟,当你失败时,总有几只猪在笑。。。

搜狐网友:离岛║Bombastic Love
评论:小时候认为流血了就是很严重的事,不管疼不疼,先哭了再说.

天猫网友:請讓我們相遇
评论:坐地铁,是一项糅合太极,柔道,缩骨功的综合性运动。

新闻转自网络媒体,如有侵权,请与我们联系:1160322105@qq.com责编:admin